雄性禿治療市場- 按治療類型（藥物{局部、口服}、設備{雷射帽、梳子、頭盔}）、按性別（男性、女性）、按藥物類型（處方藥、非處方藥）、按最終用途和預測, 2024 - 2032

Androgenetic Alopecia Treatment Market - By Treatment Type (Pharmaceutical {Topical, Oral}, Device {Laser Cap, Comb, Helmet}), By Gender (Male, Female), By Medication Type (Prescription, OTC), By End-use & Forecast, 2024 - 2032

出版日期: 2024年04月25日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在該領域臨床試驗和研發進步的推動下，2024 年至 2032 年間，全球雄性禿治療市場的複合年成長率將達到 7.6%。 AGA，俗稱男性或女性型禿髮，影響著全球數百萬人，為有效治療創造了龐大的市場。近年來，突破性的研究催生了新的治療方法。例如，2024 年 1 月，HopeMed 將其雄性禿治療推進到 II 期試驗。這家中國製藥公司在其催乳素受體抗體在一期研究中取得積極成果後啟動了二期招募。該醫院最近開始招募 II 期試驗，以評估其單株抗體 HMI-115 治療雄性禿的效果。

先進的臨床試驗正在探索創新的解決方案，包括基因療法、幹細胞療法和針對脫髮潛在機制的新型藥物製劑。對 AGA 所涉及的遺傳和分子途徑的日益深入的了解為標靶治療鋪平了道路，為更有效和個性化的治療帶來了希望。此外，生物技術和醫療技術的進步正在提高這些治療的精確度和功效。隨著研究的不斷進展，更有效率、更安全、更持久的 AGA 解決方案的承諾正在推動這一充滿活力的領域的需求和投資不斷增加。

整體雄性禿治療行業規模根據治療類型、性別、藥物類型、最終用途和地區進行分類。

該設備領域將在 2024 年至 2032 年經歷嚴格的發展。這些設備為傳統藥物治療提供了便捷的替代方案，吸引了尋求有效且方便用戶使用的解決方案的個人。此外，設備技術的不斷創新提高了治療效果，使其成為脫髮男性和女性的有吸引力的選擇。因此，AGA 治療設備的市場不斷擴大，滿足了對有效頭髮修復方法不斷成長的需求。

從 2024 年到 2032 年，女性部分的雄性禿治療市場收入將出現顯著的複合年成長率。隨著越來越多的女性尋求有效的解決方案，市場已經推出了適合女性需求的治療方法，包括局部解決方案、口服藥物以及富血小板血漿(PRP) 和低強度雷射療法(LLLT) 等先進療法。此外，專門針對女性脫髮的研究的成長帶來了更有效、更有針對性的治療方法，進一步刺激了需求。這一轉變反映出人們越來越認知到解決女性 AGA 問題的重要性。

歐洲雄性禿治療市場將在 2024 年至 2032 年呈現出值得稱讚的複合年成長率。這包括局部米諾地爾、口服非那雄胺以及富血小板血漿 (PRP) 療法和低強度雷射療法 (LLLT) 等新選擇。歐洲市場對尖端研究和開發的重視帶來了更有效、個人化的治療選擇。此外，社會轉向優先考慮外表和福祉，這導致整個非洲大陸對 AGA 治療的需求不斷成長。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Apira Science, Inc. (iGROW Laser)
Aurobindo Pharma
Cipla, Inc.
Curallux, LLC
Dr. Reddy's Laboratories Ltd.
Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
Johnson & Johnson Services, Inc.
Lexington Intl., LLC
Merck & Co., Inc.
Theradome Inc.

簡介目錄

Product Code: 9219

Global Androgenetic Alopecia Treatment Market will witness 7.6% CAGR between 2024 and 2032, driven by advancements in clinical trials and research and development in the field. AGA, commonly known as male or female pattern baldness, affects millions worldwide, creating a substantial market for effective treatments. Recent years have seen groundbreaking research leading to novel therapeutic approaches. For instance, in January 2024, HopeMed advanced its androgenetic alopecia treatment to Phase II trials. The China-based pharmaceutical company initiated Phase II recruitment following the positive outcomes of its prolactin receptor antibody in a Phase I study. The hospital commenced recruitment for a Phase II trial to evaluate its monoclonal antibody HMI-115 for androgenetic alopecia recently.

Advanced clinical trials are exploring innovative solutions, including gene therapy, stem cell treatments, and novel pharmacological agents that target the underlying mechanisms of hair loss. The growing understanding of genetic and molecular pathways involved in AGA has paved the way for targeted therapies, offering hope for more effective and personalized treatments. Furthermore, advancements in biotechnology and medical technology are enhancing the precision and efficacy of these treatments. As research continues to progress, the promise of more efficient, safe, and long-lasting solutions for AGA is driving increased demand and investment in this dynamic field.

The overall androgenetic alopecia treatment Industry size is classified based on the treatment type, gender, medication type, end-use, and region.

The device segment will undergo rigorous development from 2024 to 2032. Devices such as low-level laser therapy (LLLT) caps, microneedling rollers, and scalp cooling systems have gained popularity due to their non-invasive nature and ease of use. These devices offer a convenient alternative to traditional pharmacological treatments, attracting individuals seeking effective and user-friendly solutions. Additionally, the continuous innovation in device technology enhances treatment efficacy, making them an appealing option for both men and women experiencing hair loss. As a result, the market for AGA treatment devices is expanding, meeting the growing demand for effective hair restoration methods.

The androgenetic alopecia treatment market revenue from the female segment will register a notable CAGR from 2024 to 2032. Traditionally considered a male issue, AGA affects a substantial number of women, causing distress and impacting self-esteem. As more women seek effective solutions, the market has responded with treatments tailored to female needs, including topical solutions, oral medications, and advanced therapies like platelet-rich plasma (PRP) and low-level laser therapy (LLLT). Additionally, the growth of research specifically focused on female hair loss has led to more effective and targeted treatments, further fueling demand. This shift reflects a growing recognition of the importance of addressing AGA in women.

Europe androgenetic alopecia treatment market will showcase a commendable CAGR from 2024 to 2032. European consumers are becoming more proactive about addressing hair loss, leading to higher adoption rates of both traditional and innovative treatments. This includes topical minoxidil, oral finasteride, and newer options like platelet-rich plasma (PRP) therapy and low-level laser therapy (LLLT). The European market's emphasis on cutting-edge research and development has led to more effective, personalized treatment options. Additionally, societal shifts towards prioritizing appearance and well-being are contributing to the growing demand for AGA treatments across the continent.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of androgenetic alopecia
  - 3.2.1.2 Technological advancements in treatment
  - 3.2.1.3 Growing awareness about alopecia treatment options
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Technological landscape
3.7 Start-up scenario
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Pharmaceutical
- 5.2.1 Topical
- 5.2.2 Oral
5.3 Device
- 5.3.1 Laser cap
- 5.3.2 Laser comb
- 5.3.3 Laser helmet
5.4 Other treatment types

Chapter 6 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Male
6.3 Female

Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Prescription
7.3 OTC

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Dermatology clinics
8.3 Homecare settings
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa